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Abstract: 
This semiotic analysis demonstrates how pharmaceutical companies 
strategically frame depression within the hotly contested terrain of direct-to-
consumer (DTC) advertising. The study tracks regulation of the 
pharmaceutical industry, relative to DTC advertising, including recent industry 
codes of conduct. Focusing on the antidepressant category, and its three 
major brands—Paxil (GlaxoSmithKline), Prozac (Eli Lilly), and Zoloft (Pfizer)—
this comparative study analyzes 7 years of print advertising following 
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deregulation in 1997. The authors glean themes from within the advertising 
texts, across the drug category and within individual-brand campaigns. The 
findings indicate that DTC advertising of antidepressants frames depression 
within the biochemical model of causation, privileges benefits over risks, fails 
to adequately educate consumers, and frames depression as a female 
condition. The authors close with commentary on the potential implications, 
with particular focus on the new codes of conduct, and offer suggestions for 
future research. 
We must ask ourselves: “Are these ads, which we know are costing 
billions, properly educating patients or just peddling expensive 
products?” 
                Bill Frist, Senate Majority Leader (Thomaselli, 2005, n.p.) 
  
On August 2, 2005, the Pharmaceutical Research Manufacturers 
of America (PhRMA) released its voluntary code of conduct for direct-
to-consumer (DTC) advertising of pharmaceuticals (Appendix A). The 
release of these guidelines reflects the pharmaceutical industry’s 
efforts to refurbish its tarnished image in the wake of drug recalls and 
growing criticism of DTC advertising (Thomaselli, 2005). Yet, for an 
industry that spends U.S. $4 billion on its advertising (Thomaselli, 
2005), only time will tell if this public relations effort also ultimately 
benefits consumers. 
Concerns about the best interests of consumers are at the heart 
of the heated debate about DTC advertising (Hollon, 2005; Mehta & 
Purvis, 2003; “The New Face,” 2005; Paul, Handlin, & Stanton, 2002; 
Thomaselli, 2005). Proponents claim that DTC advertising is a powerful 
educational tool that increases awareness about health issues, offers 
consumers choices in their health care, and encourages medication 
compliance (Calfee, 2002; Mehta & Purvis, 2003; “The New Face,” 
2005). Opponents charge that DTC advertising is a biased 
informational resource that does not adequately explain side effects 
and negatively affects the doctor-patient relationship, needlessly 
driving up drug costs (Davis, 2000; Hollon, 2005; Holtz, 1998; Lexchin 
& Mintzes, 2002; Mehta & Purvis, 2003; “The New Face,” 2005; Paul et 
al., 2002). 
Previous studies addressing DTC advertising have, in general, 
quantitatively examined content and effects (Foote & Etheredge, 2000; 
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Hollon, 2005; Holtz, 1998; Kravitz et al., 2005; Lexchin & Mintzes, 
2002; Parker & Delene, 1998; Wilkes, Bell, & Kravitz, 2000), 
addressed information utility and consumer response (Calfee, 2002; 
Huh, Delorme, & Reid, 2004; Mehta & Purvis, 2003; Pinto, Pinto, & 
Barber, 1998; Vatjanapukka & Waryszak, 2004; Wilkes et al., 2000), 
and analyzed physicians’ attitudes to DTC advertising (Copeland, 
2001; Hollon, 2005; Holtz, 1998; IMS Health, 1998; Kravitz et al., 
2005; Sylvain, 2005). However, few studies have provided qualitative, 
in-depth analysis of texts as a means of exploring message content 
and their implied meanings. Even fewer have focused on a single drug 
category— antidepressants. 
Overall, the literature on DTC advertising of antidepressants is 
limited. Studies by Goldman and Montagne (1986) and Stimson (1975) 
address this category; however, their work does not reflect advertising 
since deregulation. Hansen and Dawn’s work (1995) addresses 
portrayals of females who are elderly, whereas Lõvdahl, Riska, and 
Riska (1999) examined this category internationally. Kravitz et al. 
(2005) published their groundbreaking study on consumer requests for 
antidepressants and the subsequent effects on prescribing rates. 
Hollon (2005), Holtz (1998), Kravitz et al. (2005), Mehta and Purvis 
(2003), and Paul et al. (2002) implied the need for studies that 
address message content within DTC advertising. Hollon (2005) and 
Kravitz et al. (2005) suggested the need is particularly salient for drug 
categories that are either controversial or address vulnerable 
populations, both of which apply to antidepressants. We believe that 
the current study, focusing on how DTC print advertising of 
antidepressants in Time and Reader’s Digest frames depression, is 
significant. 
DTC Advertising and Depression 
Direct-to-consumer advertising of prescription drugs has been 
defined as “any promotional effort by a pharmaceutical firm to present 
prescription drug information to the general public through the lay 
media” (Kessler & Pines, 1990, p. 2410). However, more recent 
literature suggests that DTC advertising generally refers to the 
traditional print and television advertising. In today’s marketplaces, 
any DTC marketing will necessarily involve multiple layers of 
marketing communications. However, for the current study when 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Communication Inquiry, Vol. 30, No. 2 (April 2006): pg. 163-188. DOI. This article is © SAGE Publications and 
permission has been granted for this version to appear in e-Publications@Marquette. SAGE Publications does not grant 
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from 
SAGE Publications. 
4 
 
referring to DTC advertising, we refer to traditional advertising and not 
promotion. 
The pharmaceutical industry utilizes the advertising 
effectiveness model, which focuses on exposure, awareness, and 
action. This model 
holds that (1) advertisement exposure raises consumer 
awareness of conditions and treatments; (2) increased 
awareness motivates patients to seek medical care and request 
drug therapy; and (3) patients’ requests lead, ceteris paribus, to 
increased prescribing. Drug manufactures endorse this model to 
the tune of $3.2 billion per year. (Kravitz et al., 2005, p. 1999) 
It is interesting to note that the United States is the only industrialized 
country that utilizes this model because it is the only industrialized 
country, other than New Zealand, that permits DTC advertising 
(Hollon, 2005). 
The American Psychiatric Association (APA, 2000) describes 
depression as a clinical course “characterized by one or more Major 
Depressive Episodes, without a history of ever having had a manic, 
mixed or hypomanic episode, and not due to a general medical 
condition or substance-induced mood disorder” (p. 345). Symptoms of 
major depression, four of which must be present for a diagnosis, 
include changes in appetite, weight or sleep patterns, decreased 
energy, feelings of worthlessness or guilt, difficulty concentrating or 
making decisions, or recurrent thoughts of death or suicide (APA, 
2000). 
The APA (2000) stated that treatment options for depression 
include psychotherapy (including cognitive and behavioral therapies), 
drug therapy, physical exercise, and electro-convulsive therapy. Some 
studies suggest that psychotherapy, especially the cognitive approach, 
can be highly effective (Gardner, 2001). Psychotherapy is also 
considered to be equally effective to drug therapy in cases of mild to 
moderate depression (Altshuler, Hendrick, & Burt, 1998). Still other 
studies suggest that drug therapy or a combination of drug and 
psychotherapy are effective (Altshuler et al., 1998; Carmen, Russo, & 
Miller, 1981; Copeland, 2001). The number of patients who were 
depressed and were treated with prescription drugs increased from 
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37.3% in 1987 to 74.5% in 1997 (Altshuler et al., 1998). At the same 
time, the use of psychotherapy declined slightly, despite its recognized 
effectiveness (Altshuler et al., 1998; Kotulak, 2002; Vedantam, 2002). 
Furthermore, the “percentage of patients who are helped by psycho-
therapeutic drugs is much lower than commonly claimed” (Valenstein, 
1998, p. 165). Gender also appears to complicate diagnosis with 
diagnosis being consistently higher among females (Altshuler et al., 
1998; Copeland, 2001; Nadelson & Dickstein, 1998; Weiss & 
Lonnquist, 1997), at a rate of three to one to males (Copeland, 2001; 
Gardner, 2001). 
Depression carries social stigma and is often still considered a 
taboo subject. The Mayo Clinic (“Mental Illness and Stigma,” 2005) 
describes stigma as a mark of disgrace or shame, which often fuels 
inaccurate perceptions of depression. Silenced by social stigma, some 
consumers are reticent to discuss depression or seek information. 
Stigma and overlapping symptoms can complicate depression 
diagnosis. Thus it is fair to suggest that DTC advertising of 
antidepressants may target a vulnerable population (Altshuler et al., 
1998; Carmen et al., 1981; Copeland, 2001; Hollon, 2005; Kravitz et 
al., 2005), and it is this vulnerability that makes DTC advertising of 
antidepressants among the most controversial (Altshuler et al., 1998; 
Copeland, 2001; Kravitz et al., 2005). 
Medical literature suggests two main theories of causation: the 
biochemical theory, also known as the medical model, and the psycho-
social theory. The biochemical theory suggests that mental health 
disorders arise “from internal causes . . . resulting in impaired social 
functioning” (Weiss & Lonnquist, 1997, p. 75). This theory focuses on 
irregularities in brain chemistry to conceptualize depression. The 
psycho-social theory suggests that stressful personal and social 
situations are the explanation for most depression. Stressful situations 
may include poverty, marital discord, death of significant others, and 
low self-esteem (Freden, 1982). Scholars in psycho-social traditions 
point out that many of the depression-inducing life experiences are 
associated with demographic factors that include gender (Stoppard, 
2000). 
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The Pharmaceutical Industry and Advertising 
Regulation 
Pharmaceutical manufacturers have been advertising for nearly 
70 years. The Food and Drug Administration (FDA) implemented 
regulation for the pharmaceutical industry in 1938. This early 
regulation addressing advertising to physicians is still the standard by 
which all drug advertising is judged; however, much has changed 
since 1938. First, advertisers are more skilled at research than ever 
before, and audience segmentation is now highly sophisticated. 
Second, new media have emerged, and advanced technology has 
enhanced advertisement production quality. Finally, consumers’ 
desires for, and access to, information has rapidly expanded. 
Nonetheless, only two major changes have occurred in FDA regulations 
for the pharmaceutical industry since 1938. 
First, in 1985, DTC advertising in print took off when a 
government notice stated that “current regulations governing 
prescription drug advertising provide sufficient safeguards to protect 
consumers” (Holtz, 1998, p. 202). Despite the fact that the FDA 
regulations from 1938 focused on advertising to physicians, these 
same standards are applied to consumer advertising. Specifically, DTC 
print advertisements must include brief summaries to fulfill FDA 
requirement (Holtz, 1998). This simply means that advertisers must 
list the same information in consumer advertisements that they list in 
physician advertisements, with no consideration for the educational 
variance between consumers and physicians (Holtz, 1998). 
Second, in 1997, the FDA relaxed its restrictions on broadcast 
DTC advertising. Since then, antidepressants have become one of the 
most heavily advertised drug categories (Rosenthal, Berndt, Donohue, 
Frank, & Epstein, 2002). The relaxed restrictions and new focus on 
consumers has led to an “explosion” of DTC advertising (Paul et al., 
2002), including huge increases in print advertising budgets (Bell, 
Wilkes, & Kravitz, 2000; Paul et al., 2002). The limited range of 
advertised drug types suggests that the drugs chosen for intensive 
advertising are those that consumers may be most receptive to, not 
necessarily those that are in the best interest of overall consumer 
health. “Just 20 prescription drugs account for about 60 percent of the 
total industry spending on DTCA” (Hollon, 2005, p. 2030). 
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Advertising spending across the pharmaceutical industry is 
extensive, with some advertising agencies focusing exclusively on this 
lucrative category (Courtney, 2003). In 2002, Paxil, handled by 
McCann-Erickson Consumer Health, was number 8, and Zoloft, then 
handled by Deutsch, was number 20, on the list of 20 top DTC drugs 
advertised. Paxil had advertising expenditures of $91,418,000, while 
$65,547,00 was spent on Zoloft (“The Tipping Point,” 2003). Pfizer, 
Zoloft’s parent company, was the top spending advertiser for DTC 
pharmaceuticals, while GlaxoSmithKline, the parent company of Paxil, 
was the number 2 spender on DTC advertising (“The Tipping Point,” 
2003). In 2001, Lilly’s patent on Prozac expired. Had the Prozac brand 
still been on the market in 2003, there is no doubt it too would have 
been on the top spenders list. 
By 1998, the pharmaceutical industry was spending $1.3 billion 
annually on DTC advertising, reflecting “a 20-fold increase over 1991 
spending, and more than U.S. companies spent on advertising beer” 
(Paul et al., 2002, p. 565). A 134% increase in pharmaceutical sales 
between 1997 and 2000 reflects the fruits of this advertising 
expenditure (Paul et al., 2002). During this same period, print media 
expenditures also ballooned from $573 million to $898 million, 
representing a 57.3% increase (Paul et al., 2002). By 2003, $3.2 
billion was being spent on DTC advertising (Hollon, 2005; Kravitz et 
al., 2005; Paul et al., 2002; Sylvain, 2005). Hollon (2005), in an 
editorial in the Journal of the American Medical Association, called this 
spending an “uncontrolled experiment” (p. 2030). 
Concerns of DTC Advertising 
The current study addresses six major concerns of DTC 
advertising. First, DTC advertising may not as effectively educate 
consumers as the pharmaceutical industry claims (Hollon, 2005; Holtz, 
1998; Kravitz et al., 2005; Lexchin & Mintzes, 2002; Paul et al., 
2002). The brief summaries required by the FDA do not address the 
educational variances between consumers and physicians (Holtz, 
1998), nor does their placement on a separate page enhance the 
advertising’s educational value (Hollon, 2005). The separation between 
brief summaries and the color image advertisements are far from the 
educational tool that the pharmaceutical companies claim (Hollon, 
2005; Vatjanapukka & Waryszak, 2004). 
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Second, balance between risk and benefit information is lacking. 
Weak regulation has allowed the pharmaceutical companies to focus 
on the benefits of the drugs and downplay their risks (Hollon, 2005; 
Holtz, 1998; Paul et al., 2002; Sylvain, 2005; Vatjanapukka & 
Waryszak, 2004). “The standard practice seems to be to list the top 
three (risks); however, this may be grossly inadequate” (Holtz, 1998, 
p. 215). The lack of clear risk information is one of the strongest 
rallying points for opponents of DTC advertising (Davis, 2000; Lexchin 
& Mintzes, 2002; Mehta & Purvis, 2003; “The New Face,” 2005). 
Third, concerns about the impact of DTC advertising on the 
doctor-patient relationship remain (Hollon, 2005; “The New Face,” 
2005; Paul et al., 2002; Sylvain, 2005). Direct-to-consumer 
advertising adversely affects prescribing rates, which go up “several 
fold” when patients request a drug, suggesting that “physicians may 
not be the stalwart intermediary that the law assumes” (Kravitz et al., 
2005, p. 2000). Furthermore, a study by Paul et al. (2002) states that 
close to 80% of physicians oppose DTC advertising because they feel it 
impedes their ability to provide the best possible care to their patients. 
Fourth, the costs of prescription drugs continue to rise. The 
excessively high cost of advertising has driven up the price of 
prescription drugs across all categories (Hollon, 2005; Paul et al., 
2002). Skyrocketing marketing budgets may ultimately affect the 
ability of many consumers to afford needed medications (Hollon, 2005; 
Holtz, 1998; Kravitz et al., 2005; Paul et al., 2002), as the costs of 
prescription drugs have reached an all-time high (Sylvain, 2005; 
Vatjanapukka & Waryszak, 2004). 
Fifth, the FDA does not have the resources to effectively enforce 
its own regulations (Hollon, 2005; Wilkes, 1992), whereas 
pharmaceutical companies seem to have ever-deepening pockets. A 
study by Wilkes et al. (2000) suggested that 30% of DTC 
advertisements potentially violated five or more FDA standards, and 
40% did not provide a balanced account of information. The need to 
attend to the public outcry over DTC advertising and recent drug 
recalls has created a public relations opportunity for PhRMA, which 
released the pharmaceutical industry’s new code of conduct. Industry 
executives quickly heralded the codes as groundbreaking, whereas 
critics assailed the codes as a “softball approach” (Thomaselli, 2005). 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Communication Inquiry, Vol. 30, No. 2 (April 2006): pg. 163-188. DOI. This article is © SAGE Publications and 
permission has been granted for this version to appear in e-Publications@Marquette. SAGE Publications does not grant 
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from 
SAGE Publications. 
9 
 
The sixth and final concern is specific to the antidepressant drug 
category. It appears that DTC advertising of antidepressants 
predominately targets women (Altshuler et al., 1998; Carmen et al., 
1981; Copeland, 2001; Gardner, 2001), promoting stereotypical 
assumptions about depression and exacerbating the underdiagnosis of 
males and overdiagnosis of females (Copeland, 2001; Gardner, 2001). 
Codes of Conduct 
These pharmaceutical industry’s codes of conduct (Appendix A), 
like other industries’ codes of conduct, are not binding; rather they 
may be voluntarily adopted by individual drug manufacturers. “There 
are no restrictive features in the 15-point code of conduct” and as a 
chief marketing officer stated, “It’s better to self-regulate than to have 
somebody else tell you how to conduct your business” (Thomaselli, 
2005, n.p.). The codes did not adopt the one-to two-year moratorium 
on DTC advertising suggested by many drug industry critics and 
supported by the medical community. PhRMA, however, is planning to 
establish an office of accountability, to which any signatory company is 
bound (Thomaselli, 2005). Congress or the FDA could impose more 
regulatory measures, although the underfunding of the FDA (Hollon, 
2005) suggests that more regulations are probably not on the horizon. 
Thus, it seems that these codes, as a proactive strike by the PhRMA, 
appear to be an attempt to head off any future regulations. 
Having discussed various aspects of depression, the 
pharmaceutical industry, and its regulation, we now set forth the 
following three research questions. The over-arching research question 
guiding this study is, how has DTC antidepressant advertising framed 
depression causation and recovery? Two subquestions are also 
explored. First, how are risks and benefits symbolically represented in 
the advertisements? Second, what role does gender play, if any, in 
how depression is framed within the advertisements? 
Theoretical Framework 
Semiotic decoding of advertising texts helps contextualize the 
framing of messages. Thus, semiotics and frame theory provide 
insightful perspectives for examining the symbolism and themes within 
DTC advertising. Semiotic theory suggests that signs are selected and 
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organized into codes or thematic paradigmatic chains (Fiske, 1990). 
Central to semiotics is de Saussure’s (1998) work, which suggests that 
all paradigms emerge through cultural and social experiences. Even 
the simplest sign has a meaning relevant only to those with knowledge 
of the social and cultural context in which it emerges. Signs connoting 
meaning are iconic (illustrative forms that are associated with 
particular objects), indexical (logical, systemic signs whose 
connections are based on shared understandings), and symbolic (signs 
that emerge out of cultural and social practices; Peirce, Hartshorne, 
Weiss, & Burks, 1994). The signified collides with the signifier creating 
a fluid and highly intimate relationship with the reader. The signified 
ultimately embodies salient (Entman, 1991) and resonant (Schwartz, 
1973) messages, which form the context or thematic frame (Eco, 
1984). 
Barthes (1977) took us deeper into the social and cultural realm 
of semiotic theory. He suggested that signs appear as natural items; 
however, the power structure within our cultural and social world is 
expressed semiotically through the signification of the sign. Meanings 
within signs are postponed; and hence their meaning only emerges 
later within the broader social and cultural context in which the texts 
circulate. This is particularly insightful for advertising texts, as their 
persuasive power is predicated on the authorship of the text being 
interactive; that is, the author is removed or “dislocated,” (Barthes, 
1977) allowing the reader to take ownership of the text. In the 
process, the signifiers and the signified emerge as part of a broader 
systemic infrastructure as the authors of the advertising text recede, 
becoming archaic (Sturrock, 1979). Texts themselves have no integrity 
because they are part of a larger system. Thus, the text becomes an 
intermediary between author and reader. The advertising text, as 
intermediary, thus becomes part of the cultural world that forms social 
reality. 
Barthes (1975) offered five codes for semiotic analysis: (a) 
hermeneutic orders the sequence of signs; (b) actional defines the 
sequence of movement within the text; (c) semic catalogues meanings 
within the text; (d) symbolic explores oppositional structures in the 
text; and (e) referential connects the text to the extratextual or 
historical reality. Barthes actually disparaged the idea of realism. 
Rather, he suggested that because of the fluidity of signs, realism is 
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fleeting and the “continuity of a text is a deception” (Sturrock, 1979, 
p. 75). Thus, intertextuality and history offer the only hope for 
grounding the text. Barthes’ semiotic codes form a fluid model and are 
thus insightful for advertising analysis, as they suggest that reality is 
ever altering and there is no single author. Advertisements are a 
conglomeration of multiple internal authors (copywriter, art director, 
creative director, planner, client, and more), and the meanings within 
advertising texts are dependent on external authorship (readers 
decoding the advertisement within their cultural and social 
framework). Discourse circulates fluidly around the text, and this 
suggests the power of the text to frame or articulate meaning (Bowie, 
2001). 
At a macro level, frame theory provides a window into the social 
and cultural norms of the world in which individuals live, helping them 
make meaning of various experiences and events. From a 
microperspective, frame theory helps us understand how individuals 
make sense of their lived experiences, how individuals sort and 
organize the complex stimuli of everyday life (Creed, Langstraat, & 
Scully, 2002). Framing can be seen as a process of constructing social 
reality in which the producers of mediated texts and the receivers of 
those texts interact (Scheufele, 1999). In such light, framing helps 
construct “affirmative action” (Gamson, 1992). Social reality is thus 
constructed through mediated texts, such as advertisements, and 
often takes precedence over lived experiences (Gitlin, 1980). 
The framing of social reality becomes possible only when 
advertisements have personal resonance (Schwartz, 1973) and 
salience (Entman, 1991), all of which leads to selective social reality 
(Entman, 1991). To frame is to select some aspects of a perceived 
reality and make it more salient in a visual text (Entman, 1991). The 
quality of being salient and resonant is what makes the signified 
noteworthy and memorable. Furthermore, what is omitted is as 
important as what is selected (Entman, 1991). Salience and resonance 
are achieved when the messages embedded within the advertising 
text, the signified, are consistent with the cultural or social belief 
system; thus social reality comes to life through the advertising text. 
Selection, salience, and resonance are pivotal to advertising analysis. 
Together, semiotics and frame theory allow us to more definitely 
access the persuasive intentions of the producers. In this sense, 
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semiotics and frame analysis are highly compatible for advertising 
analysis. Their application has been extended to various social 
scientific traditions, including journalism and a wide range of mass 
communication studies, and its popularity has grown since its 
introduction. 
Method 
In the current study, a print advertisement is defined as either a 
“single page” advertisement or a “spread” (two pages facing one 
another). The advertisements analyzed here are image ads, an 
industry term that means advertisements that focus on the perceived 
benefits of the product rather than the physical features of the product 
itself (“product ad”). Furthermore, in pharmaceutical advertisements 
there is an additional page listing the brief summary, as required by 
the FDA. These brief summaries are not included in the analysis. 
Suffice it to say that the brief summaries accompanying each 
advertisement are always printed in black and white with 
extraordinarily small print, use highly complex medical terminology, 
and appear on the page following the image ad. Finally, the brief 
summaries never appear on a page directly next to the image ad, so 
the image ads and the legally required brief summaries are never 
viewed simultaneously. 
Six years of print advertisements from Reader’s Digest and Time 
were gathered from August 1997 (the month the FDA enacted its 
latest deregulation) to August 2003. Reader’s Digest and Time were 
selected because of their high circulation. They are the top two 
magazines with the highest subscription rate according to MediaMark 
(2002). A MediaMark (2002) survey found that Reader’s Digest has a 
readership of 43,029,000, whereas Time has a readership of 
23,900,000. This same study found that among primary readership 
14% of Time’s readers indicate a “considerable interest in advertising,” 
whereas 16.8% of Reader’s Digest’s readers indicate a “considerable 
interest in advertising.” In addition, Reader’s Digest skews toward 
women, whereas Time skews slightly toward men (MediaMark, 2002), 
forming a more balanced readership overall. Finally, both have large 
audiences, high subscription rates, and significant interest in 
advertising among readers, further enhancing the rationale for their 
selection. 
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The examined print advertisements represent the three major 
brands advertised during this time: Prozac, Zoloft, and Paxil (examples 
of each brand’s advertisements are included in Appendices B, C, & D). 
Twenty-seven advertisements appeared during this time. Six Prozac 
advertisements appeared in Time and four in Reader’s Digest. Six 
Zoloft advertisements appeared in Time and three in Reader’s Digest. 
Six Paxil advertisements appeared in Time and two in Reader’s Digest. 
A sampling of advertisements from across 10 randomly selected 
magazines (every seventh consumer magazine was pulled from a local 
public library shelf for October 1999 and May 2002) confirms that the 
same ads ran across multiple media. 
It is notable that Prozac’s advertising only ran from August 1997 
to April 1998, yet it accounts for the highest placement in these 
publications during the entire period of analysis. Being the first brand 
to advertise in the DTC venue may account for this high, early media 
placement. Zoloft, with the second highest media buy, ran 
advertisements from May 2001 to September 2002. Paxil, the leading 
seller among antidepressants, has the smallest media buy, with 
sporadic placement in 1999, 2000, and 2001, and extensive placement 
only in 2002. 
Because of space limitations, an in-depth analysis of each 
advertisement is impossible. Thus, the current study uses a “purposive 
sampling” (Lindlof & Taylor, 2002, p. 120) of ads that exemplify 
thematic paradigmatic chains within each brand campaign and 
subsequently demonstrate the thematic framing of depression 
causation and recovery by each brand. Although selected 
advertisements bear strong similarity to others in the campaigns, the 
purposive choice represents “their relevance to the research question, 
analytical framework, and explanation . . . being developed in the 
research” (Schwandt, 2001, p. 233). To that end, headlines and 
taglines, visuals, and the placement of copy and visuals (photographs 
or illustrations) are discussed in terms of semiotics and frame theory 
to illustrate how the thematic framing moves across all the 
advertisements within each brand’s campaign. 
The following presents study findings based on examining 
advertisements for each of the three antidepressants of interest. 
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“Welcome back.” Prozac™ 
Eli Lilly was the first pharmaceutical manufacturer to begin DTC 
advertising for antidepressants with its Prozac brand. Lilly was also the 
first to cease advertising, most likely in anticipation of its soon-to-
expire patent. The Prozac campaign consists of four 2-page spreads 
utilizing visual metaphors to construct oppositional codes (Appendix 
B). On the left-hand page, a graphically illustrated iconic sign 
symbolizes depression, and on the right-hand page the iconic sign 
symbolizes recovery. A semic code is created through culturally 
relevant seasonal signifiers, setting up a deeper coding system that 
becomes extratextual as readers engage with historically bound 
cultural understandings of the seasons. The iconic signs on the left are 
always weak or incomplete, signifying depression, while the iconic 
signs on the right are always strong and fully formed, signifying 
recovery. The actional coding signifies that no matter the season one 
withers under the strain of depression and blossoms when it is 
resolved with Prozac. The iconic signs are strongly supported by the 
headlines, which rest beneath them. The font is simple, bolded, and 
reverses out of highly color-saturated backgrounds. The oppositional 
metaphoric paradigm plays out with the visuals, or iconic signs, and 
headlines are grounded in the hermeneutic nature of the seasons. 
 
Color becomes a semic code representing depression with dark 
blue, gray, and red, and recovery with yellow, bright blue, and green. 
Color also has obvious seasonal signification such as red and green for 
Christmas and yellow and blue for spring. The simplicity of the iconic 
signs creates a nonthreatening and thus engaging signifier. The use of 
saturated colors, a simple typeface, graphic icons, and rhythmic 
headlines form a simple, yet highly sophisticated, paradigm of 
depression framed by the seasons: recovery is simple with 
pharmaceuticals. Cultural connotations are grounded in seasonal 
themes with holiday joy, the budding of spring, the warmth of 
sunshine, and the security of togetherness. These recovery 
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connotations are rooted in the morphed visuals, which become 
signified by the presence of the sunny Prozac logo, whose o is a sun, 
the semic code for recovery. The actional codes, which suggest the 
sequence of events within these advertisements, lead directly to the 
logo, which in turn links recovery unambiguously to the Prozac brand 
name and thus creates an unmistakable referential code for 
biochemical recovery. 
A rhythmic pattern of copy flows across the entire campaign. 
The copy stresses the oppositional paradigmatic chains grounded in 
the symbolic codes. The headlines, “Depression 
hurts/shatters/isolates/saddens,” link seamlessly to the iconic visuals. 
The tagline, “Welcome back,” reinforces the signified actional code that 
recovery is easily available with Prozac. The words of the tagline 
rhythmically repeat the messages in the headlines, thus reinforcing the 
overall extratextual framing that depression can be simply erased with 
pharmaceuticals. The transition lines of the body copy, “Depression is . 
. . /It’s a real illness with real causes ...” form semic codes linked to 
the iconic visual signifiers above each headline. Early in the body copy, 
the semic construction of biochemical causes begins. “Some people 
think you can just will yourself out of depression. That’s not true.” A 
simplistic explanation of depression follows, with a listing of principal 
symptoms, and this leads to a biochemical actional code or call to 
action with the copy line, “The medicine doctors now prescribe most 
often is Prozac™.” Minimal disclaimers and a few “mild side effects” 
are then listed within the image ad itself. The only reference to 
nonpharmaceutical treatment options, a single line of copy (of nearly 
50 lines), suggests the possibility of psychotherapy, but only after one 
has begun taking Prozac. The body copy closes with actional codes 
framed 
 
This semiotic analysis of these advertisements helps illuminate 
how seasonal social reality is constructed and utilized to frame 
depression causation as conversely natural and out of an individual’s 
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control. This biological paradigm takes precedence over lived 
experiences (Gitlin, 1980), and in the process, salient social and 
cultural signifiers become the referential codes for depression. As 
salience frames social reality (Entman, 1991), the seasonal signifiers 
set up the framing of pharmaceuticals as the only viable treatment 
option for depression. With seasonal causation for depression framed 
as natural, and thus biological, the framing of depression recovery 
rests equally naturally in pharmaceuticals. Using resonant everyday 
life seasonal experiences (Schwartz, 1973), Lilly frames Prozac as the 
biochemical solution to a natural problem rooted in the consumer’s 
biological nature and simply triggered by seasonal experiences; thus 
constructed reality supercedes lived experiences. Ultimately, 
oppositional codes suggest a subtle but rather ironic framing, which 
signify that seasonal celebrations are simply moments in time when 
individuals’ biological depression emerges. 
“When you know more about what’s wrong, you 
can help make it right.” Zoloft™ 
Pfizer began running advertisements for its Zoloft brand in early 
2001 and continued through late 2002. The campaign consisted of four 
advertisements (Appendix C). Those in Time were single-page 
advertisements, and those in Reader’s Digest were spreads. The 
content does not change; however, the layout shifts slightly to 
accommodate the differing formats. This campaign, like Prozac’s, 
featured illustrated iconic signs along with the copy. The Zoloft 
campaign adds an additional illustrative icon, a medicalized diagram 
whose semic code “demonstrates” the chemical reactions of Zoloft 
within the brain thus expanding the paradigmatic chain leading directly 
to the biochemical model of depression causation and treatment. Each 
advertisement is executed in black and white, which connotes the 
seriousness of the illness, yet the simplicity of the drawings of the 
Zoloft icon (or egg, as it is sometimes referred to) and the “medical 
diagram” oppositionally imply simplicity. The ovalesque shape of the 
Zoloft icon, signifying a pill, referentially enhances the medicalization 
of depression. 
Human features ascribed to the Zoloft icon, such as eyes, hair, 
and mouth, come to signify depression in its human form. The human 
references become part of the extratextual experience of depression, 
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thus allowing semic codes to be placed on the icon. A contrasting spike 
in the line across the top of the icon signifies a tuft of hair. Other lines 
and circles combine to connote eyes. Subtle curving lines graphically 
signify tears, surprise, or anxiety. A simple, curved stroke near the 
bottom of the icon signifies a mouth, often downturned in a frown or 
wrinkle, connoting sadness. A drop shadow beneath the Zoloft icon 
signifies groundedness and movement, further signifying the human 
qualities ascribed to the inanimate Zoloft icon. Smooth motion lines 
around the Zoloft icon connote running, and when combined with 
squiggled “facial” lines connote fear. Wiggly motion lines connote 
shaking and thus are referential codes signifying panic. The absence of 
motion lines signifies isolation, building referential codes for 
depression. Furthermore, by utilizing the illustrative inanimate form to 
create the Zoloft icon, oppositional symbolic codes emerge. These 
optional codes allow depression to be at once human and chemical. 
Creating referential signs of humanness, while not showing a human, 
serves to reduce the stigma of depression. Thus the tagline, “When 
you know more about what’s wrong, you can help make it right,”™ 
becomes individualized and acceptable. With stigma reduced, the you 
becomes an individual abstraction, and the symptoms of depression 
become at once less threatening, more manageable, and personal. 
You, now signified as detached from the depression, codifies the 
medical model as the manageable solution to “your” problem. 
With the stigma reduced, the actional codes lead directly to the 
medicalized diagram, a highly simplistic drawing connoting “chemical 
imbalance” and the change that occurs “with Zoloft.” These captions 
define the semic code within the diagram of nerve endings and brain 
chemicals, signified by crudely drawn circles or dots. Without Zoloft, 
there are few dots. However, the subhead, resting beneath the 
medicalized diagram states, “Prescription Zoloft works to correct this 
imbalance.” Thus, the dots signifying Zoloft become the extratextual 
referential signs of recovery. Symbolically, the power of recovery is 
grounded in the chemical reaction—the dots that signify Zoloft. 
Ultimately, both illustrated icons (the Zoloft icon and the medicalized 
diagram) come to signify that with Zoloft “ . . . you can make it right.” 
A multiple series of bolded headlines codify depression 
symptoms, leading to a highly simplistic description of depression that 
supports the coding within the medicalized diagram. 
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Headlines 
“You know why you feel the weight of sadness.”  
“You may feel exhausted, hopeless, and anxious.”  
“Things just don’t feel like they used to.” 
The first headline begins the hermeneutic code circularly linking 
the headline to the visual sign of the Zoloft icon. In the case of feeling 
“the weight of sadness,” the Zoloft icon is under a “heavy” rain cloud. 
The shadow beneath it, along with the cloud, rain, and tears form 
semic codes for weighty sadness. Midway through the body copy 
actional codes for the medical model are employed with “Only your 
doctor can diagnose depression,” which implies that only a doctor can 
cure depression, which reinforces the detachment codified by the 
inanimate Zoloft icon. Brief side effects follow, and a final call to 
action, “Talk to your doctor about Zoloft, the #1 prescribed brand of 
its kind. Call . . . for more information,” sets up actional codes. As with 
the Prozac advertisements, the cursory listing of mild side effects has 
the intended effect of framing the side effects as minor and thus 
negating the “brief summary” on the following page. 
Gitlin’s (1980) perspective that social reality takes precedence 
over other experiences frames these advertisements. The social 
realities framed by the Zoloft icon, be they “weighty” sadness under a 
“heavy” cloud or the “fearsome” grip of anxiety under the “shadow” of 
a looming hand, are known consumer realities. They have salience 
(Entman, 1991) and cultural resonance (Schwartz, 1973). The graphic 
framing of depression as chemically bound, framed within the 
biochemical model, offers readers the opportunity to “select” 
information that on the surface appears educational. Yet the selective 
framing (Entman, 1991) of depression is limited and unmistakably 
biochemical. The oppositional construction of the detached Zoloft icon, 
along with the use of the personal pronoun you, referentially 
establishes personal resonance (Schwartz, 1973), whereas the 
symbolically informational medicalized diagram works to frame a 
highly complex illness simplistically. These simple, friendly, and 
approachable black-and-white illustrated advertisements frame and 
organize depression as an easily understood biochemical imbalance. 
Everyday life, so simply organized (Creed et al., 2002), frames the 
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problem as simply resolved “with Zoloft.” For “When you know more 
about what’s wrong, you can help make it right,” with “prescription 
Zoloft.” 
“Your Life Is Waiting.” Paxil™ 
Direct-to-consumer advertising of today’s number-1 selling 
antidepressant, Paxil, began appearing in print in 1999 and continues 
to date. The strategic focus across the campaign is anxiety (Appendix 
D). Unlike Prozac and Zoloft advertisements, the visuals in all Paxil 
advertisements employ models as indexical signs. As with Prozac and 
Zoloft, oppositional themes frame the campaign. Unlike Prozac and 
Zoloft, whose campaigns had highly consistent imagery and copy, the 
Paxil campaign had wider variation in imagery and layout. Yet, like 
Prozac and Zoloft, the Paxil campaign had consistency in copy content. 
Thus, multiple ads are analyzed. 
The campaign utilizes symptoms, as copy, to create repetitive 
subheads that visually form a symbolic wall of words, literally 
separating the anxious and nonanxious models. Through this 
separation, isolation becomes a symbolic oppositional code for anxiety. 
The female models are always signified as anxious and separated from 
the male models who are nonanxious. The headline, “What’s standing 
between you and your life?” forms an actional code paradigmatically 
linking anxiety directly on the female model. Beneath this main visual 
is a small close-up photograph of the female model embracing a young 
male model. The sign formed by embracing “mother” and “son” comes 
to signify recovery and is strategically placed between signifiers of 
isolation and the logo signifying chemical recovery. Actional codes 
drive the copy. “A chemical imbalance could be to blame. And life can 
feel difficult ALL DAY. That’s why you need relief ALL DAY.” The overall 
hermeneutic code begins with the headline, “What’s standing between 
you and your life?” and ends with the Paxil logo and tagline, “Your life 
is waiting!” 
Another advertisement uses semic codes of floating symptoms 
as copy to signify the anxiety of isolation, much like the wall of words 
from the previous advertisements. This signification is heightened by 
the oppositional symbolic codes of a blurred crowd surrounding the 
crisp image of an anxious female model. A split headline, “Millions 
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suffer from chronic anxiety,” literally cuts through the model’s body, 
suggesting referential codes to the broader world and her isolation 
from it. The second part of the split headline, “Millions could be helped 
by Paxil,” is placed beneath her body on a calming yellow background, 
creating semic codes of groundedness all located in the Paxil brand. 
The hermeneutic code definitively orders the sequence of anxiety, 
depression, and recovery within the biochemical model. 
In another advertisement, semic coding is apparent in the 
choice of the color blue, which suggests the extratextual context of 
“feeling blue.” Following the same thematic strategy as demonstrated 
previously, before-and-after visuals signify the biochemical model. The 
advertisement begins with a questioning headline, “Has social anxiety 
put your life on hold?” The use of questioning headlines engages the 
reader in actional codes, encouraging movement into the body of the 
ad, where the subhead, “You are not alone,” signifies that the answer 
lies with Paxil. An iconic wall continues to be utilized symbolically, 
representing isolation. This time, models lean against a wall holding 
their heads in their hands. One advertisement features a male and the 
other a female. Significantly, the male is cropped tightly; at a glance 
gender signification is muted. The female is cropped more broadly 
making the signification of femininity exceedingly clear. Visual 
signification of depression is paradigmatically linked with the subhead 
“put your life on hold.” Symptoms are listed within the body copy and 
lead to bolded copy stating that “Paxil is the only medication . . . 
approved by the FDA.” The FDA, signifying an authoritative education 
code, links into the referential code for the biochemical model. When 
the biochemical model is established, signification of recovery is 
seamlessly linked to Paxil. 
The logo and a “survey” are contained within a series of broken 
lines signifying a coupon. The use of the boxed coupon style signifies 
containment and thus the power of Paxil to contain anxiety. Actional 
codes such as boxes to check, a circled logo, and the broken lines 
forming the coupon itself encourage engagement with the text and 
thus the brand. “You may want to cut this out and show it to your 
doctor” implies a direct reference to the doctor-patient relationship. 
Across the Paxil campaign, 74% of the models are female, 
whereas 26% are male. Females are signified as depressed 96% of the 
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time whereas males are codified as depressed only 13%. By contrast, 
no more than 5% of all advertisements are males signified as 
depressed. A model was judged to be depressed by its overall visual 
representation (sad face, head in hands, etc.), its association with the 
copy elements referring to the symptoms of depression (e.g., 
sleeplessness, loneliness, etc.), and references to visual and textual 
elements that represent happiness (e.g., smile, hugging a child, etc.). 
The resulting semic codes signify males as stable and supportive while 
signifying females as anxious and unstable. Despite the strikingly 
gendered visual referent system, the copy remains gender neutral. 
Visual signs within the text have more salience over copy, however 
(Entman, 1991), and constructed social reality takes precedence over 
lived experiences, thus the paradigmatic effect supports the overall 
gender bias of females as depressed. 
The Paxil campaign quite literally, through a systemic 
infrastructure (Sturrock, 1979) of walls and boxes, frames depression 
and anxiety as biochemical problems, easily resolved with Paxil. 
Oppositional codes grounded in isolating distance, using before-and-
after visual images, suggest the power of the visual text (Entman, 
1991). Grounded in salient selectivity (Entman, 1991), codes of 
isolation become salient triggers, and the questioning headlines 
heighten anxiety. Referential codes from the boxed survey, to the 
authority signified within the FDA, to significations of recovery in an 
embrace, construct affirmative action (Gamson, 1992) and frame the 
solution to anxiety and depression as biochemical. With 96% of all 
images signifying depression as a feminine problem, by using female 
models, selective salience (Entman, 1991) is powerfully articulated. 
The campaign frames anxiety as grounded in everyday life social 
experiences (Gitlin, 1980), yet the coded text signifies it as biologically 
female. As visual texts always dominate (Entman, 1991), the 
feminization of depression by GlaxoSmithKline and its number-1 
selling antidepressant, Paxil, is unmistakable. 
Conclusions 
Returning to the overarching question of how DTC advertising of 
antidepressants frames depression, causation, and recovery, the 
current study strongly articulates a biochemical framing in which 
selective and salient codes (Entman, 1991) dominate the framing of 
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depression. On the surface, this comes as no surprise considering the 
product category is pharmaceuticals. Furthermore, we do not dismiss 
the possibility that depression has a biological component. However, 
the larger concern is about how narrowly causation is framed and how 
cultural and social practices are used to symbolize (Peirce et al., 
1994); not actual practices but rather distorted frames of social reality 
(Gitlin, 1980). Certainly, framing causation and recovery as naturally 
biochemical forms a very compelling argument for utilizing drug 
therapy. At the same time, though, it marginalizes the psycho-social 
causes for depression, thus minimizing the potential for a broader 
discussion about depression’s impact on society or conversely the 
social causes of depression. Narrowing the frame to biochemical is the 
true point of danger because in doing so reality becomes fleeting 
(Barthes, 1975) and individuals living in situations that are inherently 
stressful, anxiety producing, and/or depressing are marginalized. Thus 
selective social reality (Entman, 1991) becomes finite, making 
individuals responsibility loom large. 
Using social conditions and lived experiences as hooks or 
triggers, every advertisement analyzed constructs as resonant 
(Schwartz, 1974) and salient social reality that takes precedence over 
all lived experiences (Entman, 1991). When resonance is established, 
the advertising strategically shifts the focus from broader social 
experiences and conditions to the individual, while social conditions 
and causation recede. Reflecting Entman’s (1991) proposition that 
omissions are highly salient, the problem of depression is placed 
squarely on the individual and her or his biology. Contrarily, 
salvation—constructed through paradigmatic chains (Fiske, 1990)—is 
linked to an individualized solution: pharmaceuticals. Thus, as texts 
take precedence over reality, the truly salient question is not how 
antidepressants (or other drugs) are advertised to consumers but 
whether we should be advertising pharmaceuticals to consumers at all. 
Unfortunately, this debate is not on the table. Successful DTC 
advertising of antidepressants is all about the bottom line, 
necessitating an inextricable link to biology— not serious consumer 
education, balanced risk, and benefit information; protection of the 
doctor-patient relationship; affordable drugs available to all; or 
concern for gender equity. DTC advertising of antidepressants is, of 
course, all business, and so are PhRMA’s newly proposed codes of 
conduct. 
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The first subresearch question addresses how risks and benefits 
are symbolically framed in DTC advertisements of antidepressants. We 
suggest that risks are appallingly underprivileged. As Entman (1991) 
suggested, omission has high salience. Omissions, along with the fluid 
discourse (Bowie, 2001), frame recovery as biochemical signified by 
pharmaceuticals. The power of this framing affirms that benefits are 
highly privileged. To that end, antidepressants are framed as a quick 
fix to what is truly a larger and more complex problem. Considering 
that the product category is pharmaceuticals and the fact that the use 
of drugs is predicated on serious health conditions, minimizing risks 
seems at the least problematic and at the worst dangerous and 
unethical. With risks symbolically minimized within these image 
advertisements, and virtually lost in the complex language and 
obscure placement of the brief summaries, the health care information 
provided through DTC advertising is seriously compromised because 
the “continuity of a text is a deception” (Sturrock, 1979, p. 75). The 
claims that DTC advertising is educational are erroneous on this point 
alone. Furthermore, these advertisements selling consumers a quick 
fix, and not too subtly promoting self-diagnosis, confound the doctor-
patient relationship. Without an unvarnished and accessible 
understanding of the overall risks and benefits and treatment options, 
consumers are not well served. When it comes to risk information and 
treatment options, especially for at-risk individuals, the standards 
must be raised and the doctor-patient relationship must be protected. 
The lived experiences of patients must supersede constructed social 
reality. 
The second subresearch question explores how gender plays a 
role in the framing of depression within DTC advertising of 
antidepressants. The number-1 selling brand, Paxil, clearly and 
saliently frames depression as an overwhelmingly female disease. 
Within the Prozac and Zoloft campaigns, gender construction is subtle, 
with neutralized semic codes of gender intentionally embedded in 
iconic visuals. The gender neutrality within semiotic content may well 
be a strategic tactic to engage men and women, with the intent of 
engaging women through the men in their lives or tapping into 
women’s greater propensity to seek medical care. However, this is 
purely speculative. It is the intersection of the biochemical model with 
salient semic codes for femininity that is most disturbing. This 
combination has deep historical, referential salience, and thus the 
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power to perpetuate the stereotype of females as biologically 
depressive obscures the psycho-social factors that significantly affect 
females’ lives— from poverty to abuse to discrimination. Finally, the 
consequences of framing depression as predominately female will only 
perpetuate the overdiagnosis among females and underdiagnosis 
among males. 
Individualized quick fixes, rooted in the biochemical paradigm, 
negate the larger and significantly more pressing question of the 
impact of depression and its root causes for society at large. This 
paradigm privileges constructed reality over lived experiences (Gitlin, 
1980). Selective omissions (Entman, 1991) seem to be the rule, rather 
than the exception, and a systemic infrastructure (Sturrock, 1979) 
promotes deception. Limited educational value, an abhorrent 
minimization of risks, intrusion on the long-privileged doctor-patient 
relationship, rising drug costs, limited regulation, and the perpetuation 
of gendered stereotypes risk leaving consumers more depressed and 
discouraged than ever before. 
Advertising of pharmaceuticals may not be new; however, the 
intensity of DTC advertising, particularly antidepressants, should be a 
red flag to all. The salience of their construction and the power of their 
omissions (Entman, 1991) should spur us on to critically analyze these 
deceptive texts. With this in mind, we suggest that the voices of 
consumers need to be heard more often in the literature, as they are 
the ultimate interpreters of DTC advertising. In addition, no current 
study gives voice to the individuals who create these advertisements, 
and as Barthes suggested, one cannot study texts “in isolation from 
their mode of production” (as cited in Sturrock, 1979, p. 64). 
Furthermore, a comparative study of advertisements produced before 
and after implementation of the new PhRMA codes of conduct could 
offer insights into the impact of these new codes. The words of 
Senator Frist call us to seriously consider whether these 
advertisements are “‘properly educating patients or just peddling 
expensive products’” (Thomaselli, 2005, n.p.). 
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Appendix A 
Pharmaceutical Industry Issues DTC Ad Guidelines 
Softball Approach Rejects Calls for Restrictions or 
Moratorium 
Text of PhRMA Principles 
PhRMA Guiding Principles on Direct to Consumer Advertisements About 
Prescription Medicines 
To express the commitment of PhRMA members to deliver DTC 
communications that serve as valuable contributors to public health, 
PhRMA has established the following voluntary guiding principles. 
1. These Principles are premised on the recognition that DTC 
advertising of prescription medicines can benefit the public 
health by increasing awareness about diseases, educating 
patients about treatment options, motivating patients to contact 
their physicians and engage in a dialogue about health 
concerns, increasing the likelihood that patients will receive 
appropriate care for conditions that are frequently under-
diagnosed and under-treated, and encouraging compliance with 
prescription drug treatment regimens. 
2. In accordance with FDA regulations, all DTC information should 
be accurate and not misleading, should make claims only when 
supported by substantial evidence, should reflect balance 
between risks and benefits, and should be consistent with FDA 
approved labeling. 
3. DTC television and print advertising which is designed to market 
a prescription drug should also be designed to responsibly 
educate the consumer about that medicine and, where 
appropriate, the condition for which it may be prescribed. 
4. DTC television and print advertising of prescription drugs should 
clearly indicate that the medicine is a prescription drug to 
distinguish such advertising from other advertising for 
nonprescription products. 
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5. DTC television and print advertising should foster responsible 
communications between patients and health care professionals 
to help patients achieve better health and a more complete 
appreciation of both the health benefits and the known risks 
associated with the medicine being advertised. 
6. In order to foster responsible communication between patients 
and health care professionals, companies should spend an 
appropriate amount of time to educate health professionals about 
a new medicine or a new therapeutic indication before 
commencing the first DTC advertising campaign. In determining 
what constitutes an appropriate time, companies should take into 
account the relative importance of informing patients of the 
availability of a new medicine, the complexity of the risk-benefit 
profile of that new medicine and health care professionals’ 
knowledge of the condition being treated. Companies should 
continue to educate health care professionals as additional valid 
information about a new medicine is obtained from all reliable 
sources. 
7. Working with the FDA, companies should continue to responsibly 
alter or discontinue a DTC advertising campaign should new and 
reliable information indicate a serious previously unknown safety 
risk. 
8. Companies should submit all new DTC television advertisements 
to the FDA before releasing these advertisements for broadcast. 
9. DTC television and print advertising should include information 
about the availability of other options such as diet and lifestyle 
changes where appropriate for the advertised condition. 
10. DTC television advertising that identifies a product by name 
should clearly state the health conditions for which the medicine 
is approved and the major risks associated with the medicine 
being advertised. 
11. DTC television and print advertising should be designed to 
achieve a balanced presentation of both the benefits and the risks 
associated with the advertised prescription medicine. Specifically, 
risks and safety information in DTC television advertising should 
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be presented in clear, understandable language, without 
distraction from the content, and in a manner that supports the 
responsible dialogue between patients and health care 
professionals. 
12. All DTC advertising should respect the seriousness of the health 
conditions and the medicine being advertised. 
13. In terms of content and placement, DTC television and print 
advertisements should be targeted to avoid audiences that are 
not age appropriate for the messages involved. 
14. Companies are encouraged to promote health and disease 
awareness as part of their DTC advertising. 
15. Companies are encouraged to include information in all DTC 
advertising, where feasible, about help for the uninsured and 
underinsured. 
 
Source: Thomaselli (2005).                                                                                       
Note: DTC = direct-to-consumer; PhRMA = Pharmaceutical Research Manufacturers of 
America. 
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Appendix B 
Prozac Advertisements 
 
 
 
 
 
 
Appendix C 
Zoloft Advertisement 
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Appendix D (continued) 
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